Parkinson s research in UCC: Lifestyle factors and improving therapies

Size: px
Start display at page:

Download "Parkinson s research in UCC: Lifestyle factors and improving therapies"

Transcription

1 Parkinson s research in UCC: Lifestyle factors and improving therapies Professor Aideen Sullivan University College Cork

2 What happens in the brain in Parkinson s? MIDBRAIN STRIATUM Movement Healthy brain Parkinson s brain Motor symptoms RIGIDITY RESTING TREMOR POSTURAL INSTABILITY BRADYKINESIA

3 What happens in the brain in Parkinson s? What are we trying to prevent /slow down? 1. Gradual loss of dopamine neurons that control movement 2. A protein called alpha-synuclein builds up (aggregates) and spreads through the nervous system 3. As the disease progresses, many areas of the nervous system are affected and this causes a multitude of different symptoms Lewy body

4 But it s not just dopamine neurons that are affected Gastrointestinal issues Mood disorders Loss of smell Sleep disturbances Swallowing & speech problems Bladder issues Cognitive impairment Non-motor symptoms have a huge impact on patients

5 Why does Parkinson s happen? For most patients, the cause of Parkinson s is unknown Risk factors: Age Genetics Environment (Pesticides) Genetic causes e.g. alpha-synuclein, LRKK2, parkin, PINK1, DJ-1

6 Researching to improve therapies and earlier diagnostics for Parkinson s A Centre of Excellence in Neurodegeneration OUR GOAL Apply our knowledge to develop better therapies, and improve quality of life for people living with major brain diseases 40 Research teams

7 Researching to improve therapies for Parkinson s: How are we doing this? People body / tissue / cell / molecular changes lifestyle / environment Models laboratory models for testing disease mechanisms People Therapies Diagnostics new therapies for clinical trials life-style interventions new diagnostic approaches Ultimate aim: to understand causes of Parkinson s and translate findings to better therapies that prevent or slow down the disease

8 Researching to improve therapies for Parkinson s: How are we doing this? Metabolism Longevity Nurturing factors Neurotransmission Cell survival Gut-brain axis Microbiome Protein Metabolic health Cell /longevity waste disposal control Insulin/IGF1 Lifestyle factors Environment Inflammation Vascular

9 Researching to improve therapies for Parkinson s: Why are we doing this? MIDBRAIN Parkinson s brain STRIATUM Movement Add dopamine or mimic its actions Effective in the short-term Do not stop disease progression Disabling side-effects with longterm use

10 Researching to improve therapies for Parkinson s: How are we doing this? 1. Neurotrophic factors natural proteins that nurture dopamine neurons in the developing brain

11 Researching to improve therapies for Parkinson s Non-motor symptoms greatly affect patients quality of life 2. Focus on non-motor symptoms - new laboratory models (cognitive symptoms, gastrointestinal symptoms) - study on sleep, diet and mood (collaboration with Cork Parkinson s Support Group)

12 Preventing Parkinson s by understanding lifestyle factors for healthy ageing

13 Parkinson s will be best prevented both by understanding lifestyle factors that may slow down its progress and by developing new therapies that target the cell and molecular systems that cause the disease

14 Management Team Cora O Neill Aideen Sullivan Suzanne Timmons Yvonne Nolan Gerard O Keeffe Aisling Ryan John Cryan Team Barry Boland Geraldine Boylan Jason Chan Danny Costello Tom Cotter Simon Cronin Ruslan Dmitriev Ted Dinan Tony Foley Collette Hand Niall Hyland John McCarthy Justin McCarthy Will Molloy Deirdre Murray Nicole Muller Ken O Halloran Olivia O Leary Dervla O Malley Denis O Mahony Siobhain O Mahony Sean O Sullivan Colm O Tuathaigh Orna O Toole Dmitri Papkovsky Mark Rae Annalisa Setti George Shorten Brian Sweeney Andre Toulouse Christian Waeber Paul Young Affiliated PIs Stephen Byrne Kellie Dean Susan Joyce Eric Moore Tom Moore Mary McCaffrey Caitriona O Driscoll Rosemary O Connor

15 Cork neuroscience centre Funding and support The Netherlands Brain Bank Translational Research Access Programme (TRAP) UCC

16 So hope for a great sea-change On the far side of revenge. Believe that further shore Is reachable from here. Believe in miracle And cures and healing wells

USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research

USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE The Michael J. Fox Foundation for Parkinson s Research MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission We are

More information

Treatment of Parkinson s Disease: Present and Future

Treatment of Parkinson s Disease: Present and Future Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing

More information

John. F. Cryan. Brain Research in Ireland (An Overview of Successes, Opportuni;es and Challenges)

John. F. Cryan. Brain Research in Ireland (An Overview of Successes, Opportuni;es and Challenges) http://apc.ucc.ie Brain Research in Ireland (An Overview of Successes, Opportuni;es and Challenges) John. F. Cryan Professor & Chair Department of Anatomy & Neuroscience & Principal Inves:gator, Alimentary

More information

Parkinson s disease: Can we move in the right direction?

Parkinson s disease: Can we move in the right direction? Snapshots of Doctoral Research at University College Cork 2012 Parkinson s disease: Can we move in the right direction? Shane Hegarty Department of Anatomy and Neuroscience, UCC Imagine losing the control

More information

University of Applied Sciences. February 9, 2017, Fribourg, Switzerland

University of Applied Sciences. February 9, 2017, Fribourg, Switzerland Gut Microbiota: A Key Regulator of Brain and Metabolic Function Dr. Cristina Torres Fuentes & Prof. John F. Cryan APC Microbiome Institute, University College Cork, Cork, Ireland University of Applied

More information

III./3.1. Movement disorders with akinetic rigid symptoms

III./3.1. Movement disorders with akinetic rigid symptoms III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.

More information

The PD You Don t See: Cognitive and Non-motor Symptoms

The PD You Don t See: Cognitive and Non-motor Symptoms The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Assistant Professor of Neurology and Psychiatry University of Colorado Denver Goals 1) What are the most common non-motor

More information

A Gut Feeling About the Brain: The Microbiota-Gut-Brain Axis

A Gut Feeling About the Brain: The Microbiota-Gut-Brain Axis A Gut Feeling About the Brain: The Microbiota-Gut-Brain Axis Prof. John. F. Cryan MRIA Dept. Anatomy & Neuroscience and APC Microbiome Institute University College Cork Ireland @jfcryan The Language of

More information

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical

More information

The PD You Don t See: Cognitive and Non-motor Symptoms

The PD You Don t See: Cognitive and Non-motor Symptoms The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals

More information

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a

More information

Parkinson s UK Brain Bank

Parkinson s UK Brain Bank Parkinson s UK Brain Bank From Brain to Breakthrough Dr George Gveric Manager 19 October 2018 Coordinated approach Donors Relatives Information Reporting Researchers Tissue supply Quality assurance Expertise

More information

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the

More information

Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background

Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background Case Study 2: Neurological Degenerative Disease FDA Regulatory and Clinical Background Heather Benz, Ph.D. FDA Center for Devices and Radiological Health Neurological Degenerative Diseases Neurodegenerative

More information

Mercy University Hospital Cork city community

Mercy University Hospital Cork city community Mercy University Hospital Cork city community A 3-year innovative project funded by Genio/HSE An integrated service for patients and their families Providing excellent acute hospital care where necessary,

More information

Welcome and Introductions

Welcome and Introductions Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1

More information

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease 5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater

More information

Precise evaluation of motor and non-motor dysfunction in Parkinson s disease using the KINARM

Precise evaluation of motor and non-motor dysfunction in Parkinson s disease using the KINARM Precise evaluation of motor and non-motor dysfunction in Parkinson s disease using the KINARM Project lead: Dr. Ron Levy Pauline Gaprielian, Dr. Stephen H. Scott, Dr. Giovanna Pari Queen s University,

More information

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following: 1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing

More information

Welcome and Introductions

Welcome and Introductions Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing

More information

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,

More information

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for

More information

Issues for Patient Discussion

Issues for Patient Discussion onmotor complications radykinesia Screening Tools asked PD micrographia eurodegeneration Designed for Use by Family Practitioners remor on-off opamine agonists tiffness depression ostural instability wearing

More information

METHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE

METHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE METHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE Madrid, 14 de noviembre de 2017 1. THE TEAM AND THE INSTITUTIONS BEHIND

More information

Nervous System. Unit 6.6 (6 th Edition) Chapter 7.6 (7 th Edition)

Nervous System. Unit 6.6 (6 th Edition) Chapter 7.6 (7 th Edition) Nervous System Unit 6.6 (6 th Edition) Chapter 7.6 (7 th Edition) 1 Learning Objectives Identify the main parts (anatomy) of a neuron. Identify the 2 divisions of nervous system. Classify the major types

More information

PARKINSON S DISEASE 馬 萬 里. Chinese character for longevity (shou) Giovanni Maciocia

PARKINSON S DISEASE 馬 萬 里. Chinese character for longevity (shou) Giovanni Maciocia PARKINSON S DISEASE Chinese character for longevity (shou) Giovanni Maciocia 馬 萬 里 PARKINSON'S DISEASE Parkinson's disease is a clinical syndrome characterized by impairment of movement, rigidity and tremor,

More information

Using Sources in the GDP

Using Sources in the GDP Using Sources in the GDP The following are five examples of sources that you may encounter while working on your GDP project. The information contained in each of these sources (shown by screen shot) was

More information

Optimizing Clinical Communication in Parkinson s Disease:

Optimizing Clinical Communication in Parkinson s Disease: Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of

More information

WHO, WHAT, WHEN AND WHERE OF PARKINSON S DIAGNOSIS. MJFF Third Thursdays Webinar March 17, 2016

WHO, WHAT, WHEN AND WHERE OF PARKINSON S DIAGNOSIS. MJFF Third Thursdays Webinar March 17, 2016 WHO, WHAT, WHEN AND WHERE OF PARKINSON S DIAGNOSIS MJFF Third Thursdays Webinar March 17, 2016 WHAT WE LL COVER TODAY How is Parkinson s misdiagnosed? How is Parkinson s diagnosed today? Can we use DaTscan

More information

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed

More information

SNOEZELEN FOR THE PEOPLE WITH PARKINSON'S DISEASE

SNOEZELEN FOR THE PEOPLE WITH PARKINSON'S DISEASE SNOEZELEN FOR THE PEOPLE WITH PARKINSON'S DISEASE Maja Povše, University Rehabilitation Institute, Republic of Slovenia Soča ISNA-MSE'S XIII International Congress, Crete, 27.10.2016 S L O V E N I A Slovenia

More information

Modeling Parkinson s disease: systems to test gene-environment interactions

Modeling Parkinson s disease: systems to test gene-environment interactions Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)

More information

Evaluation of Parkinson s Patients and Primary Care Providers

Evaluation of Parkinson s Patients and Primary Care Providers Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,

More information

The Parkinson s You Can t See

The Parkinson s You Can t See The Parkinson s You Can t See We principally see the motor phenomena of Parkinson's disease, but is there an early stage without visible features? Might this provide a window for disease-modifying therapy?

More information

METHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE

METHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE METHOD FOR PREDICTING THE EARLY ONSET AND SEVERITY OF LEVODOPA INDUCED DYSKINESIA (LID) IN SUBJECTS DIAGNOSED OF PARKINSON S DISEASE Con el respaldo de ACCIÓ Madrid, 14 de noviembre de 2017 1. THE TEAM

More information

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age

More information

SECTION 1: as each other, or as me. THE BRAIN AND DEMENTIA. C. Boden *

SECTION 1: as each other, or as me. THE BRAIN AND DEMENTIA. C. Boden * I read all the available books by other [people with] Alzheimer s disease but they never had quite the same problems as each other, or as me. I t s not like other diseases, where there is a standard set

More information

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:

More information

Development of the National Integrated Care Pathway for Older Persons

Development of the National Integrated Care Pathway for Older Persons Development of the National Integrated Care Pathway for Older Persons 2 nd November, 2017 Cork University Hospital Dr Patrick Barry, MB,MD, FRCPI Acting Lead for Integrated Care, CUH 1 Context :Integrated

More information

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis Chapter 20 Drugs for Degenerative Diseases of the Nervous System Slide 18 Media Directory Levadopa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Alzheimer s Disease Amyotrophic Lateral

More information

UNDERSTANDING PARKINSON S DISEASE

UNDERSTANDING PARKINSON S DISEASE UNDERSTANDING PARKINSON S DISEASE WHAT IS PARKINSON S DISEASE? A progressive disease of the nervous system marked by tremor, muscular rigidity, and slow, imprecise movement, chiefly affecting middleaged

More information

How to Effectively Manage the Motor Symptoms of HD

How to Effectively Manage the Motor Symptoms of HD How to Effectively Manage the Motor Symptoms of HD Yvette Bordelon, MD, PhD Associate Clinical Professor of Neurology David Geffen School of Medicine at UCLA The information provided by speakers in workshops,

More information

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW WELCOME Parkinson s 101 for the Newly Diagnosed Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW Parkinson s Disease 101 Presenter for Today Cari Friedman, LCSW Patient and Family Service

More information

Movement Disorders: A Brief Overview

Movement Disorders: A Brief Overview Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance

More information

Investigating molecular mechanisms of progression of Parkinson s Disease in human brain

Investigating molecular mechanisms of progression of Parkinson s Disease in human brain Investigating molecular mechanisms of progression of Parkinson s Disease in human brain Murray ; C.E., Pressey ; S.N., Heywood 2 ; W.E., Hargreaves 3 ; I.P., Neergheen 3 ; V., Wauters ; S., Palkovits 4

More information

RAMBAM. Revolutionary New Treatment for Parkinson s Disease Tremors. Health Care Campus. Information Guide & Treatment Options

RAMBAM. Revolutionary New Treatment for Parkinson s Disease Tremors. Health Care Campus. Information Guide & Treatment Options RAMBAM Health Care Campus Revolutionary New Treatment for Parkinson s Disease Tremors Information Guide & Treatment Options Table of Contents Introduction 1 Parkinson s Disease Symptoms: Tremors 2 Current

More information

Novel Targets of disease modifying therapy for Parkinson disease. David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology

Novel Targets of disease modifying therapy for Parkinson disease. David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology Novel Targets of disease modifying therapy for Parkinson disease David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology Disclosures Dr. Standaert has served as a paid consultant

More information

Date of Referral: Enhanced Primary Care Pathway: Parkinson s Disease

Date of Referral: Enhanced Primary Care Pathway: Parkinson s Disease Specialist LINK Linking Physicians CALGARY AND AREA Patient Name: Date of Birth: Calgary RHRN: PHN / ULI: Date of Referral: Referring MD: Fax: Today s Date: CONFIRMATION: TRIAGE CATEGORY: REFERRAL STATUS:

More information

TILDA Policy Conference

TILDA Policy Conference TILDA Policy Conference Graham Love Chief Executive Health Research Board Mansion House, Nov 10 2014 Health Policy, 1-2 pm The HRB, Ageing & TILDA Dr Graham Love, Chief Executive, Health Research Board

More information

Headway Victoria Epilepsy and Parkinson s Centre

Headway Victoria Epilepsy and Parkinson s Centre Headway Victoria Epilepsy and Parkinson s Centre Parkinson s Overview and Medication Shannon Oatway Community Education/ Awareness Coordinator What is Parkinson s Disease? The basics It is a chronic and

More information

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials 1 Informative series of workshops featuring emerging trends in medical technology regulatory science, MDIC projects and subject matter experts sharing perspectives, progress and opportunities. Designing

More information

TUESDAY, MARCH 28, 2017 WEDNESDAY, MARCH 29, 2017 WELCOME RECEPTION (VIENNA CITY HALL)

TUESDAY, MARCH 28, 2017 WEDNESDAY, MARCH 29, 2017 WELCOME RECEPTION (VIENNA CITY HALL) KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 28, 2017

More information

Irish National Eating Disorder Conference February 23 th 2018: Development of an evidence and values based eating disorder service: the HSE approach

Irish National Eating Disorder Conference February 23 th 2018: Development of an evidence and values based eating disorder service: the HSE approach Irish National Eating Disorder Conference February 23 th 2018: Development of an evidence and values based eating disorder service: the HSE approach (...a new hope) Dr Sara McDevitt, National Clinical

More information

Enhanced Primary Care Pathway: Parkinson s Disease

Enhanced Primary Care Pathway: Parkinson s Disease Enhanced Primary Care Pathway: Parkinson s Disease 1. Focused summary of PD relevant to primary care Parkinson s Disease (PD) and Essential tremor (ET) are two of the most common movement disorders encountered

More information

10th Medicine Review Course st July Prakash Kumar

10th Medicine Review Course st July Prakash Kumar 10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS

More information

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits

More information

The Role of DOPAL in Parkinson s Disease. Karenee Demery. Copyright May, 2015, Karenee Demery and Koni Stone

The Role of DOPAL in Parkinson s Disease. Karenee Demery. Copyright May, 2015, Karenee Demery and Koni Stone The Role of DOPAL in Parkinson s Disease Karenee Demery Copyright May, 2015, Karenee Demery and Koni Stone Parkinson s disease is an incurable, neurodegenerative disease. The cause is still not fully understood.

More information

Parkinson s Foundation

Parkinson s Foundation Parkinson s Foundation PD ExpertBriefing: Diagnosis PD, Now What? Managing the First Few Years with Parkinson s Led By: Suketu Khandhar, M.D., Medical Director at Kaiser Permanente Northern California

More information

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People

More information

Parkinson s Disease. Sirilak yimcharoen

Parkinson s Disease. Sirilak yimcharoen Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically

More information

What is Parkinson s disease?

What is Parkinson s disease? What is Parkinson s disease? 2 credit hour course Parkinson s disease (PD) is a disorder caused by a loss of nerve cells in a small part of the brain called the substantia nigra. This area of nerve cells

More information

Evaluation and Management of Parkinson s Disease in the Older Patient

Evaluation and Management of Parkinson s Disease in the Older Patient Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of

More information

symptoms of Parkinson s disease EXCEPT.

symptoms of Parkinson s disease EXCEPT. M. Angele Theard, M.D Asst. Professor, Washington University, St. Louis, MO Quiz team; Shobana Rajan, M.D; Suneeta Gollapudy, MD; Verghese Cherian, M.D, M. Angele Theard, MD This quiz is being published

More information

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Pathways bolt 16/6/06 20:38 Page 1 Pa t h w a y s A PARADIGM FOR DISEASE MANAGEMENT IN Pa r k i n s o n s Disease MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Clinical diagnosis Pa r k i n s o n s disease

More information

Pilates as a modality to increase movement and improve quality of life for those suffering from Parkinson s Disease

Pilates as a modality to increase movement and improve quality of life for those suffering from Parkinson s Disease Pilates as a modality to increase movement and improve quality of life for those suffering from Parkinson s Disease Miranda Handke 23 July 2016 Comprehensive Global Format Brisbane, Australia 2015 Abstract

More information

Understanding Parkinson s Disease Important information for you and your loved ones

Understanding Parkinson s Disease Important information for you and your loved ones Patient Education Understanding Parkinson s Disease Important information for you and your loved ones This handout explains the signs, symptoms, and possible treatments of Parkinson s disease. Parkinson

More information

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000

More information

groundbreaking partnership to help many thousands of Australians, and their families, whose lives are scarred by bipolar disorder

groundbreaking partnership to help many thousands of Australians, and their families, whose lives are scarred by bipolar disorder Dear Supporter, As the leaders of the Black Dog Institute and NeuRA (Neuroscience Research Australia) we are excited that high quality research is helping us better understand causes and treatments of

More information

THIS IS NOT YOUR GRANDMOTHER S DISEASE: WHAT DOES BEING DIAGNOSED WITH PARKINSON S DISEASE MEAN TODAY?

THIS IS NOT YOUR GRANDMOTHER S DISEASE: WHAT DOES BEING DIAGNOSED WITH PARKINSON S DISEASE MEAN TODAY? THIS IS NOT YOUR GRANDMOTHER S DISEASE: WHAT DOES BEING DIAGNOSED WITH PARKINSON S DISEASE MEAN TODAY? THURSDAY MARCH 14, 2019 REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA AMERICAN

More information

Central nervous system

Central nervous system Central nervous system By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 7 th Lecture Lecture outline Review of structure & function. Symptoms, signs & tests. Specific diseases. Review of structure

More information

PD ExpertBriefing: What s in the Parkinson s Pipeline

PD ExpertBriefing: What s in the Parkinson s Pipeline PD ExpertBriefing: What s in the Parkinson s Pipeline Presented by: David G. Standaert, M.D., Ph.D. Professor of Neurology Director, Center for Neurodegeneration and Experimental Therapeutics University

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

CAREGIVER SUMMIT. The PD You Can't See: Dealing with Non-Motor Symptoms. Kaitlyn Roland, PhD. Sponsored by:

CAREGIVER SUMMIT. The PD You Can't See: Dealing with Non-Motor Symptoms. Kaitlyn Roland, PhD. Sponsored by: CAREGIVER SUMMIT The PD You Can't See: Dealing with Non-Motor Symptoms Kaitlyn Roland, PhD Sponsored by: Cognition VS Dementia Memory Executive Function Attention Bradyphrenia Visuospatial Language Hallucinations

More information

UPDATE ON RESEARCH IN PARKINSON S DISEASE

UPDATE ON RESEARCH IN PARKINSON S DISEASE UPDATE ON RESEARCH IN PARKINSON S DISEASE Charles H. Adler, M.D., Ph.D. Professor of Neurology Mayo Clinic College of Medicine Co-Principal Investigator Arizona Parkinson s Disease Consortium Arizona Study

More information

Update on Parkinson s disease and other Movement Disorders October 2018

Update on Parkinson s disease and other Movement Disorders October 2018 Update on Parkinson s disease and other Movement Disorders October 2018 DR. JONATHAN EVANS CONSULTANT IN NEUROLOGY QUEEN S MEDICAL CENTRE NOTTINGHAM Disclosures: Honoraria UCB, Britannia, Allergan, AbbVie

More information

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS

More information

Prion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice

Prion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice Prion-like propagation of alpha-synuclein aggregates in the brain of wild-type mice Nolwen L. Rey, PhD Patrik Brundin s Laboratory, Van Andel Research Institute Grand Rapids, Michigan, USA 15th Annual

More information

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually

More information

Derived copy of Nervous System Disorders *

Derived copy of Nervous System Disorders * OpenStax-CNX module: m57764 1 Derived copy of Nervous System Disorders * Shannon McDermott Based on Nervous System Disorders by OpenStax This work is produced by OpenStax-CNX and licensed under the Creative

More information

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is

More information

The Nobel Prize in Physiology or Medicine 2000

The Nobel Prize in Physiology or Medicine 2000 The Nobel Prize in Physiology or Medicine 2000 Press Release NOBELFÖRSAMLINGEN KAROLINSKA INSTITUTET THE NOBEL ASSEMBLY AT THE KAROLINSKA INSTITUTE 9 October 2000 The Nobel Assembly at Karolinska Institutet

More information

Moving fast or moving slow: an overview of Movement Disorders

Moving fast or moving slow: an overview of Movement Disorders Moving fast or moving slow: an overview of Movement Disorders Mini Medical School October 25, 2018 Heather Rigby, MD, FRCPC 2014 MFMER slide-1 2014 MFMER slide-2 Basal Ganglia Dysfunction - Movement Disorders

More information

Basal ganglia motor circuit

Basal ganglia motor circuit Parkinson s Disease Basal ganglia motor circuit 1 Direct pathway (gas pedal) 2 Indirect pathway (brake) To release or augment the tonic inhibition of GPi on thalamus Direct pathway There is a tonic inhibition

More information

Strategies for Dementia and Alzheimer s Care. Welcome and Introduction. Thank you, Why this topic? 3/9/2017

Strategies for Dementia and Alzheimer s Care. Welcome and Introduction. Thank you, Why this topic? 3/9/2017 Strategies for Dementia and Alzheimer s Care LEADERS 2017 SLIDES PREPARED FOR PREVIEW MARCH CAMILLE PAVY CLAIBOURNE, APRN, PHD. Welcome and Introduction STRATEGIES CARING AND COMMUNICATING IN CAREGIVING

More information

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE

FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE FOUNDATION OF UNDERSTANDING PARKINSON S DISEASE DEE SILVER M.D MOVEMENT DISORDER SPECIALIST MEDICAL DIRECTOR -- PARKINSON ASSOCIATION OF SAN DIEGO 1980 TO PRESENT SCRIPPS MEMORIAL HOSPITAL, LA JOLLA CA.

More information

Mind Altering Microbes: Role of Microbiota-Gut-Brain Axis in Stress-Related Disorders

Mind Altering Microbes: Role of Microbiota-Gut-Brain Axis in Stress-Related Disorders Mind Altering Microbes: Role of Microbiota-Gut-Brain Axis in Stress-Related Disorders John F. Cryan Ph.D. Professor & Chair Department of Anatomy & Neuroscience & Principal Investigator, Alimentary Pharmabiotic

More information

Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B.

Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B. UvA-DARE (Digital Academic Repository) Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B. Link to publication Citation for published version (APA): Post, B. (2009). Clinimetrics,

More information

ANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE

ANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE ANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE 21 February 217 MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission To accelerate the development

More information

Prior Authorization with Quantity Limit Program Summary

Prior Authorization with Quantity Limit Program Summary Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.

More information

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there

More information

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone

More information

PD AND FALLS J U MALLYA FALLS AWARENESS MEETING

PD AND FALLS J U MALLYA FALLS AWARENESS MEETING PD AND FALLS J U MALLYA FALLS AWARENESS MEETING 23-09-2016 PD Chronic Progressive neurodegenerative disease Motor system disorder Degeneration of Dopaminergic neurons in Substantia nigra in the midbrain.

More information

Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development

Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development Ken Marek Coalition Against Major Diseases and FDA 2014 Annual Scientific Workshop Oct 2014 Disclosure Co-founder

More information

Nervous System. Unit 6.6 (6 th Edition) Chapter 7.6 (7 th Edition)

Nervous System. Unit 6.6 (6 th Edition) Chapter 7.6 (7 th Edition) Nervous System Unit 6.6 (6 th Edition) Chapter 7.6 (7 th Edition) 1 Learning Objectives Identify the main parts (anatomy) of a neuron. Identify the 2 divisions of nervous system. Classify the major types

More information

Parkinson s Disease. Gillian Sare

Parkinson s Disease. Gillian Sare Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second

More information

CDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease

CDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease CDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease Brain Diseases Symposium, Helsinki 14 Oct 2016 Pekka Simula, CEO, Herantis Pharma Plc 1 Disclaimer This presentation

More information

ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ²

ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ² ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ² ¹ University of Medicine and Pharmacy Cluj-Napoca ² Clinical Rehabilitation Hospital

More information

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Chapter 8 Parkinsonism M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Definition of Parkinson s Disease Parkinson's disease is a progressive, neurodegenerative disease

More information

PD ExpertBriefing: The Effects of Exercise on PD

PD ExpertBriefing: The Effects of Exercise on PD PD ExpertBriefing: The Effects of Exercise on PD Led By: Margaret Schenkman, P.T., Ph.D., F.A.P.T.A. Associate Dean for Physical Therapy Education, and Director, Physical Therapy Program, University of

More information